Abivax reported mixed H1 2023 results, with a significant loss per share miss but a sales beat. Following these results, two prominent analysts lowered their price targets for ABVX, indicating a potentially negative sentiment shift despite the sales outperformance.
Abivax (ABVX) released its H1 2023 financial results, showing a larger-than-expected loss per share of $2.43 against an estimated $1.08, which is a significant negative surprise. However, the company did beat sales expectations, reporting $2.959 million versus an estimated $1.860 million. The market's initial reaction was a slight pre-market dip, suggesting the loss miss outweighed the sales beat. Following these results, Wedbush and Truist Securities analysts both maintained their ratings but lowered their price targets, indicating a reassessment of the company's valuation. This suggests a short-term negative sentiment for ABVX due to the earnings miss and analyst adjustments, potentially creating a selling opportunity for traders betting on further downside or a buying opportunity for those who believe the sales beat and long-term prospects are undervalued.